Program
ziftomenib
Also written as “Ziftomenib”.
Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Gastrointestinal Stromal Tumors · Hematologic Neoplasms, led by 2 companies.
Drug pageZiftomenib: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kura Oncology | 55 open or running | phase 3since May 16, 2025 | Jun 25, 2019 | Dec 2026phase 1 · NCT06001788 |
| Kyowa Kirinits history only | 11 open or running | phase 2since Apr 8, 2026 | Apr 8, 2026 | Mar 2027phase 2 · NCT07623616 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kura Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 25, 2019First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04067336 · 263 enrolled · United States, Belgium, Canada and more
- Jul 28, 2021Named ziftomenibINNProposed as its International Nonproprietary Name in WHO's List 125
- Aug 7, 2023Phase 1 study in Hematologic NeoplasmsNCT06001788 · 171 planned · United States, Italy, Spain
- Oct 14, 2024Phase 1 study in Gastrointestinal Stromal TumorsNCT06655246 · 135 planned · United States
- May 16, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT07007312 · 1,300 planned · United States, Australia, Belgium and more
- Oct 21, 2026Phase 1 study in Myelodysplastic SyndromesNCT07929740 · 126 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Hematologic NeoplasmsNCT06001788
- Oct 16, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04067336
- Feb 28, 2029Primary completion: phase 1 study in Myelodysplastic SyndromesNCT07929740
- Jun 2029Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT06655246
TargetBeta
“An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, ”NCIt, by rule
Other programs on KMT2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| revumenibrule | Syndax Pharmaceuticals | phase 3 | 6 |
| bleximenib | Johnson & Johnson | phase 3 | 4 |
| icovamenibrule | biomea-fusion-inc | phase 2 | 7 |
Studies
All 5 Kura Oncology leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07929740Myelodysplastic Syndromes | 1 | Not yet recruiting | Feb 28, 2029 | 126 |
| NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Recruiting | Nov 2031 | 1,300 |
| NCT06655246Gastrointestinal Stromal Tumors · United States | 1 | Recruiting | Jun 2029 | 135 |
| NCT06001788Hematologic Neoplasms · United States, Italy, Spain | 1 | Recruiting | Dec 2026 | 171 |
| NCT04067336Leukemia, Myeloid, Acute · United States, Belgium, Canada and more | 2 | Active, not recruiting | Oct 16, 2028 | 263 |
How it is read
Names in the registry
- “Ziftomenib”, 7 entries
- “ziftomenib”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Myelodysplastic Syndromes, 1 study
- Gastrointestinal Stromal Tumors, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.